🇺🇸 FDA
Patent

US 10519224

Treating headache comprising administering an antibody to calcitonin gene-related peptide

granted A61KA61K2039/505A61K2039/545

Quick answer

US patent 10519224 (Treating headache comprising administering an antibody to calcitonin gene-related peptide) held by TEVA PHARMACEUTICALS INTERNATIONAL GMBH expires Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
TEVA PHARMACEUTICALS INTERNATIONAL GMBH
Grant date
Tue Dec 31 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
23
CPC classes
A61K, A61K2039/505, A61K2039/545, A61P, A61P25/04